



Rev: A

Release Date: 03/13/2014

IVD

Wilm's Tumour1 (EP122)

Clone	EP122
Source	Rabbit Monoclonal
Cat #	PR076-6ml RTU PR076-3ml RTU CR076-0.5ml Concentrated CR076-0.1ml Concentrated
Regulatory Status	IVD

Intended Use:

This antibody is intended for use to qualitatively identify specific antigen by light microscopy in formalin fixed, paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper controls and must be made within the context of the patient's clinical history and other diagnostic tests. A qualified pathologist must perform evaluation of the test.

Summary and Explanation:

Wilms' Tumor 1 (WT1) is a transcription factor that plays an important role in cellular development and cell survival. The WT1 gene encodes a tumor suppressor gene inactivated in Wilms' tumor, recently implicated in WNT signaling through the enhancement of cytoplasmic beta-catenin (CTNNB1) degradation.

WT1 has been demonstrated in mesenchymal-derived cells and in Wilms' tumor. An antibody to WT1 is useful for the identification of malignant mesothelioma. A literature review of 88 published papers suggested that the sensitivity and specificity of WT-1 for the identification of epithelioid mesothelioma was 77% and 96%, respectively. WT1 immunoreactivity has also been detected in several types of other malignancies, including peritoneal serous carcinoma and carcinomas of the breast, ovarian, and leukemia. In hepatocellular carcinoma, the expression of WT1 is correlated with a response to chemotherapy.

Additionally, WT1 is a useful marker to differentiate desmoplastic small round cell tumors (DSRCT) from other small round cell tumors.

Immunogen: A synthetic peptide corresponding to the Nterminus of human WT1 protein

Isotype: Rabbit IgG

Reagent Provided:

Concentrated format: Antibody to WT1 is affinity purified and diluted in antibody diluent, with 1% bovine serum albumin (BSA) and 0.05% sodium azide (NaN₃).
Recommended dilutions: 1:50 – 1:100.

The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by individual laboratory.

Pre-diluted format: PathnSitu ready to use antibodies are pre tittered to optimal staining conditions. Further dilution may loose the activity and may yield to sub optimal staining conditions.

Storage Recommendations: Store at 2-8 °C. Do not use after expiration date provided on the vial.

Staining Recommendations:

Antigen Retrieval Solution: Use **Tris/EDTA Buffer(PathnSitu cat # PS009)** as antigen retrieval solution Heat Retrieval Method: Retrieve sections under steam pressure for 15 min using PathnSitu's MERS (Multi Epitope Retrieval System) then allow solution to cool for 10 minutes then transfer tissue sections/slides to distilled water.

Primary Antibody: Cover the tissue sections with primary antibody and incubate for 30 min at room temperature when used PathnSitu PolyExcel Detection System.

Detection System: Refer to PathnSitu PolyExcel detection system protocol or manufacturer's detection kit staining protocol when used other vendor detection system.

Cellular Localization: Nucleus

Positive Control: Kidney or Mesothelioma

Troubleshooting: Follow the antibody specific protocol recommendations according to data sheet provided. If unusual results occur, contact PathnSitu Technical Support at 040-2701 5544 or techsupport@pathnsitu.com.

Limitations and Warranty: There are no warranties, expressed or implied, which extend beyond this description. PathnSitu is not liable for property damage, personal injury, or economic loss caused by this product.

Bibliography:

1. Scharnhorst V, *et al.*: *Gene* 2001, 273:141-161
2. Rivera MN, *et al.*: *ProcNatlAcadSci U S A* 2009, 106:8338-8343
3. Sebire NJ, *et al.*: *ApplImmunohistochemMolMorphol*2005, 13:1-
4. King JE, *et al.*: *Histopathology* 2006, 48:223-232
5. Silberstein GB, *et al.*: *ProcNatlAcadSci U S A* 1997, 94:8132-8137
6. Acs G, *et al.*: *Int J GynecolPathol*2004, 23:110-118
7. Pritchard-Jones K, *et al.*: *Leuk Lymphoma* 1997, 27:207-220
8. Perugorria MJ, *et al.*: *Cancer Res* 2009, 69:1358-1367
9. Barnoud R, *et al.*: *Am J SurgPathol*2000, 24:830-836

WT1, EP122 antibody has been created by Epitomics Inc., using Epitomics' proprietary rabbit monoclonal antibody technology covered under Patent No.'s 5,675,063 and 7,402,409.